Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome

by Mark S. Freedman
Published 2014-11-01

Blood Neurofilament Light Chain: The Neurologist’s Troponin?

by Simon Thebault, Ronald A. Booth, Mark S. Freedman
Published 2020-11-01

Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation

by Simon Thebault, Ronald A. Booth, Carolina A. Rush, Heather MacLean, Mark S. Freedman
Published 2021-03-01

Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis

by Simon Thebault, Mohammad Abdoli, Seyed-Mohammad Fereshtehnejad, Daniel Tessier, Vincent Tabard-Cossa, Mark S. Freedman
Published 2020-06-01

Routine HIV testing among providers of HIV care in the United States, 2009.

by A D McNaghten, Eduardo E Valverde, Janet M Blair, Christopher H Johnson, Mark S Freedman, Patrick S Sullivan
Published 2013-01-01

Pain Due to Multiple Sclerosis: Analysis of the Prevalence and Economic Burden in Canada

by Charles Piwko, Olivier B Desjardins, Basil G Bereza, Marcio Machado, Barbara Jaszewski, Mark S Freedman, Thomas R Einarson, Michael Iskedjian
Published 2007-01-01

Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveill...

by Ann N Do, Eli S Rosenberg, Patrick S Sullivan, Linda Beer, Tara W Strine, Jeffrey D Schulden, Jennifer L Fagan, Mark S Freedman, Jacek Skarbinski
Published 2014-01-01

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis

by Giancarlo Comi, Mark S. Freedman, José E. Meca-Lallana, Patrick Vermersch, Byoung Joon Kim, Alexander Parajeles, Keith R. Edwards, Ralf Gold, Houari Korideck, Jeffrey Chavin, Elizabeth M. Poole, Patricia K. Coyle
Published 2020-10-01

Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis

by Peter J. Darlington, Brandon Stopnicki, Tarik Touil, Jean-Sebastien Doucet, Lama Fawaz, Morgan E. Roberts, Marie-Noëlle Boivin, Marie-Noëlle Boivin, Nathalie Arbour, Mark S. Freedman, Harold L. Atkins, Amit Bar-Or, Amit Bar-Or
Published 2018-05-01

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of m...

by Antonio Uccelli, Alice Laroni, Lou Brundin, Michel Clanet, Oscar Fernandez, Seyed Massood Nabavi, Paolo A. Muraro, Roberto S. Oliveri, Ernst W. Radue, Johann Sellner, Per Soelberg Sorensen, Maria Pia Sormani, Jens Thomas Wuerfel, Mario A. Battaglia, Mark S. Freedman, on behalf of the MESEMS study group
Published 2019-05-01

Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis

by Simon Thebault, Hyunwoo Lee, Gauruv Bose, Daniel Tessier, Mohammad Abdoli, Marjorie Bowman, Jason Berard, Lisa Walker, Carolina A. Rush, Heather MacLean, Ronald A. Booth, Sridar Narayanan, Douglas L. Arnold, Vincent Tabard‐Cossa, Harold L. Atkins, Amit Bar‐Or, Mark S. Freedman
Published 2020-05-01